Verázial Labs is once again featured in «Partner Insights», Ambit Iberia’s magazine dedicated to digital transformation in the Life Sciences sector. In this third edition, the company shares its perspective on collaboration and innovation among technology partners and companies in this industry, as well as its own role within the ecosystem.
Ambit Iberia continues to establish itself as a leading player in developing IT strategies and solutions for the pharmaceutical, medical product, and in vitro diagnostics (IVD) sectors. With a strong commitment to regulatory compliance across the entire product lifecycle, the consultancy has turned «Partner Insights» into an established reference within the Life Sciences ecosystem.
Launched in 2024, the magazine’s third edition brings together 13 exclusive interviews with Ambit Iberia’s leading technology partners. Featured companies include ValGenesis, Agilent, Andersen, Applus+ Laboratories, and Verázial Labs, which share their perspectives on the evolution and adoption of digital technologies in Life Sciences.
Through their responses, the interviews offer a range of perspectives on how innovation and new technologies are driving process modernization, improving operational efficiency, and helping companies meet the sector’s demanding regulatory requirements.
Verázial Labs on innovation and collaboration in the Life Sciences ecosystem
Verázial Labs, provider of biometric login and electronic signature solutions that ensure data integrity and regulatory compliance in pharmaceutical production processes, has once again been selected to take part in «Partner Insights», highlighting its role as a strategic Ambit Iberia partner since 2023 and its presence in all three editions of the magazine to date.
In the interview, Verázial Labs’ CEO reflects on how collaboration models in the Life Sciences sector are shifting “from purely transactional relationships toward true co-creation ecosystems.” The sector’s complex and demanding requirements make it impossible for any single company to tackle alone, which is why combining specialized expertise and knowledge has become key to reducing risk in the pharma industry.
Among his recommendations, Emilio Gallego points out the importance of prioritizing critical processes with the greatest impact on safety, quality, and regulatory compliance, and of choosing technology built specifically for these regulated environments rather than adapted after the fact. In addition he emphasizes the importance of involving teams from the beginning, noting that “technology adoption almost always fails for human reasons, not technical ones.”
The interview also highlights the accuracy and security of Verázial’s biometric software, which ensures data traceability and integrity while strengthening regulatory compliance and improving operational efficiency, even in critical environments, such as pharmaceutical clean rooms. In this context, the company introduces its latest addition to its solutions portfolio: the Verázial Band, an identification wristband that, once activated through biometrics, functions as an NFC authentication device, offering a more comfortable and efficient way to manage identification and biometric signatures, without compromising security.
On the whole, Verázial Labs’ participation in this third edition of «Partner Insights» reflects its ongoing contribution to the pharmaceutical sector’s evolution, with solutions that continue to strengthen security, efficiency, and regulatory compliance in an increasingly demanding industry.
You can download the full magazine (currently available in Spanish only) on the following page: Ambit Iberia: Partner Insights Magazine.
